BPMC - Blueprint Medicines Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
76.90
+1.44 (+1.91%)
At close: 4:00PM EDT

76.90 0.00 (0.00%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Previous Close75.46
Open75.09
Bid71.50 x 1000
Ask83.77 x 1000
Day's Range74.79 - 77.51
52 Week Range44.58 - 89.00
Volume302,073
Avg. Volume457,850
Market Cap4.057B
Beta (3Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-5.39
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est105.50
Trade prices are not sourced from all markets
  • Earnings Preview: Blueprint Medicines (BPMC) Q1 Earnings Expected to Decline
    Zacksyesterday

    Earnings Preview: Blueprint Medicines (BPMC) Q1 Earnings Expected to Decline

    Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Small-Cap Biotech Stocks to Watch Now
    Motley Fool22 days ago

    3 Small-Cap Biotech Stocks to Watch Now

    These under-the-radar stocks could be poised to make big moves in the coming months.

  • Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
    PR Newswire23 days ago

    Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock

    CAMBRIDGE, Mass., April 2, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the closing of its previously announced underwritten public offering of 4,662,162 shares of its common stock at a public offering price of $74.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $327.2 million, after deducting underwriting discounts and commissions and estimated offering expenses. Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Guggenheim Securities, LLC and Wedbush Securities Inc. acted as co-lead managers for the offering. A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with the Securities and Exchange Commission (SEC) and has become effective.

  • Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session
    Zacks24 days ago

    Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session

    Blueprint Medicines (BPMC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today
    Simply Wall St.26 days ago

    If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Investing can be hard but the potential fo an individual stock to pay off big time inspires us. You won't get it ri...

  • Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
    PR Newswire28 days ago

    Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., March 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines has granted the underwriters a 30-day option to purchase up to an additional 608,108 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock were offered by Blueprint Medicines.

  • Blueprint Medicines Expediates Filings for Key Candidates
    Zacks28 days ago

    Blueprint Medicines Expediates Filings for Key Candidates

    Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.

  • Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
    PR Newswire29 days ago

    Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., March 27, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it has commenced an underwritten public offering of $300,000,000 in shares of its common stock. In addition, Blueprint Medicines expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 in shares of its common stock in connection with the public offering. All shares of common stock will be offered by Blueprint Medicines.

  • Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress
    PR Newswire29 days ago

    Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress

    -- Avapritinib: plan to submit MAA for PDGFRα D842V mutant GIST and fourth-line GIST in Q3 2019 and NDA for advanced systemic mastocytosis in Q1 2020 -- -- BLU-667: plan to submit NDA for previously treated ...

  • 5 Cancer-Fighting Stocks to Boost Portfolio Gains
    Zacks29 days ago

    5 Cancer-Fighting Stocks to Boost Portfolio Gains

    It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.

  • 3 Cancer Treatment Stocks to Buy in March
    Motley Foollast month

    3 Cancer Treatment Stocks to Buy in March

    Find out why these oncology-focused companies stand out as great opportunities right now.

  • Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
    PR Newswire2 months ago

    Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference

    CAMBRIDGE, Mass. , March 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  ...

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in ITT, Palo Alto Networks, Enterprise Products Partners, Blueprint Medicines, Lincoln Electric, and NewMarket — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of BPMC earnings conference call or presentation 26-Feb-19 1:30pm GMT

    Q4 2018 Blueprint Medicines Corp Earnings Call

  • Blueprint Medicines Corp (BPMC) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Blueprint Medicines Corp (BPMC) Q4 2018 Earnings Conference Call Transcript

    BPMC earnings call for the period ending December 31, 2018.

  • Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
    PR Newswire2 months ago

    Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results

    -- Avapritinib NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST on track for submission to FDA in second quarter -- -- BLU-667 receives Breakthrough Therapy Designation for the treatment of RET ...

  • 3 Top Healthcare Stocks to Buy in February
    Motley Fool2 months ago

    3 Top Healthcare Stocks to Buy in February

    Canopy Growth Corporation, MyoKardia, and Blueprint Medicines are all outstanding healthcare picks this month.

  • Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
    PR Newswire2 months ago

    Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

    CAMBRIDGE, Mass. , Feb. 19, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced ...

  • Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline
    Zacks2 months ago

    Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline

    Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Markit2 months ago

    See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

    Blueprint Medicines Corp NASDAQ/NGS:BPMCView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BPMC totaled $2.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Blueprint Medicines to Present at Upcoming Investor Conferences in February
    PR Newswire3 months ago

    Blueprint Medicines to Present at Upcoming Investor Conferences in February

    CAMBRIDGE, Mass. , Feb. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  ...

  • ACCESSWIRE3 months ago

    Three Companies Using AI and Innovation to Lead Healthcare Sector

    HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence. In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves. "Artificial intelligence could also use the way we look to help us predict future disease.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT

    Q3 2018 Blueprint Medicines Corp Earnings Call

  • Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table
    Investor's Business Daily3 months ago

    Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table

    Pharma giant Eli Lilly put together its winning bid for Loxo Oncology in just 10 days ahead of the J.P. Morgan Healthcare Conference, according to documents filed Thursday with the SEC.